Trial Profile

Undifferentiated human fetal brain-derived stem cells grafted into putamina of parkinsonian patients is safe and moderately effective: a phase I clinical trial.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic stem cell therapy (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man

Most Recent Events

29 Jan 2020 New trial record
22 Jan 2020 According to a Celavie Biosciences media release, data were published in Cell Transplantation in 2018.
22 Jan 2020 According to a Celavie Biosciences media release, five year follow-up data were presented at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com